Karyopharm Therapeutics (KPTI) Tops Q2 EPS by 1c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.64), $0.01 better than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance
• BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18